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Case Presentation:
Paraneoplastic Pemphigus presenting like Toxic Epidermal Necrolysis
Discussion:
Paraneoplastic pemphigus (PNP) is an autoimmune bullous skin disease initiated by an underlying malignant 
or benign neoplasm. It was first described in 1990 by Anhalt et al. with proposed diagnostic criteria including: 
the presence of painful, progressive stomatitis, histopathologic changes of acantholysis or interface dermatitis, 
demonstration of anti-plakin antibodies, and presence of an underlying neoplasm, typically lymphoproliferative. 
Associated neoplasms include non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, 
Castleman disease, thymoma, Waldenstrom macroglobuliemia, sarcomas and malignant melanoma. This disease 
affects both males and females equally with no racial predilection. It has most often been reported in patients aged 
45-70 but has occurred in children as young as 7 years old. Patients typically present with intractable stomatitis. 
The skin eruption is variable and can range from diffuse erythema, erythematous macules and papules, scaly 
plaques, vesiculobullous lesions, erosions to exfoliative erythroderma. PNP has also been seen on biopsy in the 
gastrointestinal tract and respiratory tract mucosa. Bronchiolitis obliterans can result and be fatal to most patients. 
When it affects conjunctival tissue, it can cause severe pseudomembranous conjunctivitis that can lead to corneal 
scarring. 
Histopathologically, PNP demonstrates dyskeratosis, acantholysis, and an interface dermatitis. Direct 
immunofluorescence shows IgG and C3 deposition in the intercellular spaces of the epithelium. Indirect 
immunofluorescence on transitional epithelium such as rat bladder can show a similar pattern. Immunoprecipitation 
will show autoantibodies directed against desmoplakin, envoplakin, BPAg1, and periplakin. ELISA can be used 
to detect antibodies to desmoglein 1 and 3, anti-envoplakin and anti-periplakin autoantibodies. The differential 
diagnosis includes other blistering diseases such as bullous pemphigoid, cicatricial pemphigoid, pemphigus vulgaris, 
and epidermolysis bullosa. When mucosal surfaces are affected along with areas of denudation and skin sloughing, 
Stevens-Johnson Syndrome/Toxic epidermal necrolysis (TEN) should be considered. 
Our patient had PNP but his skin changes progressed rapidly and led to skin sloughing which presented like TEN. 
His histopathologic findings and history of an underlying malignancy supported the PNP diagnosis. Of note, Yamada 
et al described a case of PNP mimicking TEN associated with B-cell lymphoma. Managing PNP and TEN can be 
similar but medication cessation will not benefit PNP. Treatment for PNP is difficult and most patients respond poorly. 
Treating the underlying malignancy may control autoantibody production and the use of corticosteroids is generally 
the first line therapy. Skin and mucosal lesions should be treated with non-adherent wound dressings to prevent 
infection. Other immunosuppressants such as cyclophosphamide, cyclosporine A, plasmapheresis, immunophoresis, 
IV gammablobulin, and rituximab have been used but with varying results. 
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Patient: 59 year-old Caucasian male.
History of Present Illness: The patient presented to 
Lehigh Valley Hospital burn unit after being transferred from an outside 
hospital with a painful, desquamating, blistering, erythematous rash 
involving the entire body with erosions on the eyes, mouth and nasal 
mucosa. He complained of a worsening, blistering rash that began four 
months prior. His symptoms began with a sore throat and progressed 
to blisters and erosions involving his mouth, lips and neck and 
subsequently spread to his body. He initially saw his PCP who treated 
his oral lesions with several courses of antivirals under the suspicion of 
herpes simplex virus infection. However, viral cultures were negative. 
Patient had been diagnosed with B-cell lymphoma six months prior to 
presentation but his treatment was deferred pending resolution of his 
suspected HSV infection. He has a history of psoriasis, previously treated 
with adalimumab which was discontinued after the diagnosis of his 
B-cell lymphoma.
Medical/Surgical History: Follicular B-cell lymphoma, 
psoriasis, hypothyroidism
Current Medications: Valacyclovir, levothyroxine, 
citalopram, hydrocodone, triamcinolone acetonide 0.1% ointment
Previous Medications: Fluoruracil 5%, doxycycline, 
clobetasol proprionate 0.05% cream
Physical Examination: Patient has generalized exfoliative 
erythroderma with flaccid bullae and erosions covering his entire body 
surface. There are crusted hemorrhagic erosions involving his lip, 
eclabion and ectropion. 
Laboratory Data: Skin Autoantibody Profile Positive, “Monkey 
Esophagus IgG: Positive. Presence of IgG antibodies supports pemphigus 
and its variants including paraneoplastic pemphigus.” 
Patient was placed on comfort measures before ELISA and indirect 
immunofluorescence testing using rat bladder could be performed. 
Biopsy: Health Network Laboratories (1690266, 1/27/15). Right 
upper back superior: “Interface dermatitis characterized by necrotic 
keratinocytes at all levels of the epidermis. There is suprabasal 
clefting and acantholysis and a mild to moderate superficial dermal 
lymphohistiocytic infiltrate. Eosinophils are not identified.” Direct 
immunofluorescence: “Positive focal linear granular basement 
membrane of C3. IgG, few scattered cytoids; IgM: Several scattered 
cytoids; IgA, several scattered cytoids.” 
Diagnosis: Paraneoplastic Pemphigus presenting like Toxic 
Epidermal Necrolysis
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Figure 1: Generalized 
erythroderma with ectropian.
Figure 2: Chronic stomatitis 
causing hemorrhagic crusting.
Figure 3: Generalized exfoliative erythroderma.
Figure 4: Skin sloughing of his L foot.
Figure 5: Punch biopsy of Back, 
Magnification 10x. Interface dermatitis 
characterized by necrotic keratinocytes at 
all levels of the epidermis.
Figure 6: Magnification 20x.
